Literature DB >> 3166573

Bone formation induced in an infant by systemic prostaglandin-E2 administration.

H R Jørgensen1, H Svanholm, A Høst.   

Abstract

We report a case of long-term systemic administration of prostaglandin E2 (PGE2) to a newborn infant with ductus-dependent congenital heart disease. After 46 days of treatment, radiography showed cortical hyperostosis of the long bones. The child died 62 days after discontinuation of prostaglandin treatment. Histologic examination of tubular bones showed hyperostosis presumably due to prostaglandin-induced rapid formation of primitive bone. The additional finding of extensive resorption of the outer cortical surface and bone formation at the inner surface suggested a reversible phase after discontinuation of treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166573     DOI: 10.3109/17453678809149406

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  10 in total

1.  Plain film and CT observations in prostaglandin-induced bone changes.

Authors:  M A Matzinger; V A Briggs; H J Dunlap; K Udjus; D J Martin; P McDonald
Journal:  Pediatr Radiol       Date:  1992

Review 2.  Toward a cure for osteoporosis: reversal of excessive bone fragility.

Authors:  C H Turner
Journal:  Osteoporos Int       Date:  1991-10       Impact factor: 4.507

3.  Teriparatide (human PTH1-34) compensates for impaired fracture healing in COX-2 deficient mice.

Authors:  Kiminori Yukata; Chao Xie; Tian-Fang Li; Matthew L Brown; Tsukasa Kanchiku; Xinping Zhang; Hani A Awad; Edward M Schwarz; Christopher A Beck; Jennifer H Jonason; Regis J O'Keefe
Journal:  Bone       Date:  2018-02-03       Impact factor: 4.398

4.  Regulation of Nur77 gene expression by prostanoids in cementoblastic cells.

Authors:  Sanda M Moldovan; Jeanne M Nervina; Sotirios Tetradis; Paulo M Camargo
Journal:  Arch Oral Biol       Date:  2009-02-23       Impact factor: 2.633

5.  Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4.

Authors:  Chao Xie; Bojian Liang; Ming Xue; Angela S P Lin; Alayna Loiselle; Edward M Schwarz; Robert E Guldberg; Regis J O'Keefe; Xinping Zhang
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

6.  Exogenous prostacyclin, but not prostaglandin E2, produces similar responses in both G6PD activity and RNA production as mechanical loading, and increases IGF-II release, in adult cancellous bone in culture.

Authors:  S C Rawlinson; S Mohan; D J Baylink; L E Lanyon
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

7.  Increased bone growth by local prostaglandin E2 in rats.

Authors:  R S Yang; T K Liu; S Y Lin-Shiau
Journal:  Calcif Tissue Int       Date:  1993-01       Impact factor: 4.333

8.  Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates.

Authors:  Huaizhong Pan; Monika Sima; Pavla Kopecková; Kuangshi Wu; Songqi Gao; Jihua Liu; Dong Wang; Scott C Miller; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2008-05-28       Impact factor: 4.939

9.  In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells.

Authors:  Benjamin J Frisch; Rebecca L Porter; Benjamin J Gigliotti; Adam J Olm-Shipman; Jonathan M Weber; Regis J O'Keefe; Craig T Jordan; Laura M Calvi
Journal:  Blood       Date:  2009-09-02       Impact factor: 22.113

10.  Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression.

Authors:  Damian C Genetos; Clare E Yellowley; Gabriela G Loots
Journal:  PLoS One       Date:  2011-03-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.